Pfizer Other Current Assets 2010-2024 | PFE

Pfizer other current assets from 2010 to 2024. Other current assets can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • Pfizer other current assets for the quarter ending September 30, 2024 were $7.884B, a 1.72% decline year-over-year.
  • Pfizer other current assets for 2023 were $9.277B, a 7.95% increase from 2022.
  • Pfizer other current assets for 2022 were $8.594B, a 124.97% increase from 2021.
  • Pfizer other current assets for 2021 were $3.82B, a 4.77% increase from 2020.
Pfizer Annual Other Current Assets
(Millions of US $)
2023 $9,277
2022 $8,594
2021 $3,820
2020 $3,646
2019 $2,357
2018 $12,186
2017 $5,351
2016 $6,091
2015 $4,825
2014 $2,843
2013 $3,689
2012 $3,567
2011 $9,380
2010 $9,440
2009 $496
Pfizer Quarterly Other Current Assets
(Millions of US $)
2024-06-30 $7,884
2024-03-31 $8,605
2023-12-31 $8,889
2023-09-30 $8,541
2023-06-30 $8,022
2023-03-31 $8,260
2022-12-31 $8,594
2022-09-30 $6,149
2022-06-30 $5,970
2022-03-31 $4,202
2021-12-31 $3,820
2021-09-30 $7,667
2021-06-30 $7,579
2021-03-31 $7,510
2020-12-31 $3,646
2020-09-30 $6,519
2020-06-30 $2,513
2020-03-31 $2,737
2019-12-31 $2,357
2019-09-30 $6,713
2019-06-30 $12,412
2019-03-31 $12,444
2018-12-31 $12,186
2018-09-30 $2,450
2018-06-30 $2,343
2018-03-31 $2,190
2017-12-31 $5,351
2017-09-30 $2,174
2017-06-30 $1,880
2017-03-31 $2,221
2016-12-31 $6,091
2016-09-30 $3,962
2016-06-30 $3,023
2016-03-31 $2,355
2015-12-31 $4,825
2015-09-30 $2,248
2015-06-30 $2,449
2015-03-31 $2,815
2014-12-31 $2,843
2014-09-30 $2,545
2014-06-30 $2,727
2014-03-31 $3,473
2013-12-31 $3,689
2013-09-30 $7,835
2013-06-30 $9,819
2013-03-31 $9,647
2012-12-31 $3,567
2012-09-30 $8,849
2012-06-30 $9,215
2012-03-31 $9,361
2011-12-31 $9,380
2011-09-30 $9,288
2011-06-30 $9,271
2011-03-31 $8,755
2010-12-31 $9,440
2010-09-30 $494
2010-06-30 $682
2010-03-31 $490
2009-12-31 $496
2009-09-30 $231
2009-06-30 $219
2009-03-31 $299
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $151.422B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51